Aclaris Therapeutics develops prescription drug candidates, testing them in clinical trials and planning to sell approved products through partners. It last closed at $3.38 on Nov 17, down 6.24% on the day. The average 12-month price target from 2 analysts is $7.50 (+121.9% from the last close), with a high of $12.00 and a low of $3.00.
Only 2 firms rated ACRS in the past 90 days, not enough for a consensus
Average 12-month target
$7.50
▲ 121.9% upside
Based on 2 analysts who set a price target on ACRS in the past 90 days. The average target is $7.50, with a high of $12.00 and a low of $3.00, compared with the last close of $3.38.
Low $3.00Avg $7.50High $12.00
Blue marker: last close $3.38
Highest target$12.00
Average target$7.50
Lowest target$3.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 17Buy$13 → $12
WedbushDowngrade
Nov 17Hold$3
Canaccord GenuityTarget raised
Oct 31Buy$10 → $13
Canaccord GenuityInitiated
Sep 1Buy$10
LifeSci CapitalInitiated
Jun 2Buy$13
Date
Firm
Action
Rating
Price target
Nov 17
Canaccord Genuity
Target lowered
Buy
$13 → $12
Nov 17
Wedbush
Downgrade
Hold
$3
Oct 31
Canaccord Genuity
Target raised
Buy
$10 → $13
Sep 1
Canaccord Genuity
Initiated
Buy
$10
Jun 2
LifeSci Capital
Initiated
Buy
$13
Loading…
Technical Analysis
ACRS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 14% below its 20 day and 28% below its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $3.28, and the nearest resistance the Pivot at $3.42.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 9.4%/day
Key levels
$6.6052 week high+95.3%
$5.05100 day average+49.4%
$4.54200 day average+34.3%
$4.3350 day average+28.1%
$4.08Swing high (Oct 29)+20.7%
$3.8620 day average+14.2%
$3.52Pivot R1+4.1%
$3.42Pivot+1.2%
$3.38Last close
$3.28Pivot S1−3.0%
$3.25Swing low (Oct 16)−3.8%
$2.3452 week low−30.8%
Indicators
RSI (14)
36.93
Weak, oversold below 30
Neutral
MACD
-0.12
Above its signal line
Bullish
Stochastic
27.8
Middle of its range
Neutral
ADX (14)
29.5
Trending down
Williams %R
-93.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-184.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−9.6%
Change over 10 sessions
Bearish
ATR (14)
$0.32
Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 20.4%/day
Key levels
$6.6052 week high+95.3%
$5.05100 day average+49.4%
$4.54200 day average+34.3%
$4.3350 day average+28.1%
$4.08Swing high (Oct 29)+20.7%
$3.8620 day average+14.2%
$3.52Pivot R1+4.1%
$3.42Pivot+1.2%
$3.38Last close
$3.28Pivot S1−3.0%
$3.25Swing low (Oct 16)−3.8%
$2.3452 week low−30.8%
Indicators
RSI (14)
38.08
Weak, oversold below 30
Neutral
MACD
-0.24
Below its signal line
Bearish
Stochastic
16.2
Near the bottom of its range
Oversold
ADX (14)
30.0
Trending down
Williams %R
-94.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-112.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−36.5%
Change over 10 sessions
Bearish
ATR (14)
$0.69
Typical daily range, 20.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for ACRS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ACRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ACRS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ACRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACRS is in one of them and how their past ACRS trades turned out.
Aclaris Therapeutics is a pharmaceutical company based in Wayne, Pennsylvania. It develops prescription drug product candidates and tests them in clinical trials, relying on outside research organizations to run much of that work. The company plans to bring approved products to patients through outside partners, who would sell them to patients, insurers and government health programs. It also depends on outside suppliers to manufacture the drug supplies used in its trials.